Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 547 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Robust and Durable Clinical Activity of Tepotinib in Patients with METex14-Skipping... June 21, 2023 Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously... June 16, 2026 Teen Created App To Help His Non-Verbal Sister And Others Like... October 28, 2021 Cancer Won’t Wait: “I prayed she would see her daughter start... October 11, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Enzalutamide Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer EMA Recommends Granting a Marketing Authorisation for Nirogacestat Updated Oncogene-Addicted mNSCLC Living Guideline v1.3
